#1 Clinical Trials Search in Europe

Adeno-Associated Viral Vector Serotype 9 Containing The Human Sulfamidase Gene

This article discusses ongoing clinical trials for a novel gene therapy treatment targeting Mucopolysaccharidosis type IIIA, also known as Sanfilippo A syndrome. The therapy uses an adeno-associated viral vector serotype 9 containing the human sulfamidase gene (AAV9-CAG-coh-SGSH) to potentially address the underlying genetic cause of this rare metabolic disorder. The trials aim to evaluate the safety, tolerability, and initial efficacy of this innovative approach in children with Sanfilippo A syndrome.

Table of Contents

What is AAV9-hSGSH?

AAV9-hSGSH, also known as AAV9-CAG-coh-SGSH, is an investigational medicinal product being studied for the treatment of Sanfilippo A Syndrome[1]. This product is classified as a gene therapy, which means it aims to treat a disease by introducing genetic material into a patient’s cells[1].

The full name of this therapy is Adeno-Associated Viral Vector Serotype 9 Containing the Human Sulfamidase Gene. Let’s break this down:

  • Adeno-Associated Viral Vector: This is a harmless virus that has been modified to carry genetic material into cells.
  • Serotype 9: This refers to a specific type of the virus that is good at reaching brain cells.
  • Human Sulfamidase Gene: This is the healthy gene that the therapy aims to deliver to patients’ cells.

Target Condition: Sanfilippo A Syndrome

AAV9-hSGSH is being developed to treat Mucopolysaccharidosis type IIIA, also known as Sanfilippo A Syndrome[1]. This is a rare genetic disorder that primarily affects the brain and spinal cord. Children with this condition lack an enzyme called sulfamidase, which leads to the buildup of toxic substances in their cells, causing progressive brain damage[1].

How AAV9-hSGSH Works

The therapy works by delivering a healthy copy of the SGSH gene, which provides instructions for making the sulfamidase enzyme, directly into the brain[1]. The goal is for the brain cells to use this new gene to produce the missing enzyme, potentially slowing or stopping the progression of the disease.

Clinical Trial Details

A clinical trial is currently underway to test the safety and initial effectiveness of AAV9-hSGSH[1]. This is a Phase I/II trial, which means it’s one of the earliest stages of testing in humans. The main features of this trial include:

  • The therapy is administered directly into the fluid surrounding the brain (intracerebroventricular or ICV administration).
  • Patients receive a single dose of the treatment.
  • The study will test three different dose levels in different groups of patients.

Eligibility Criteria

The trial has specific criteria for who can participate[1]. Some key points include:

  • Children aged 2 years or older
  • Confirmed diagnosis of Sanfilippo A Syndrome
  • Onset of symptoms before 6 years of age
  • Ability to walk independently
  • No severe sensory deficits (like blindness or severe deafness)

There are also several exclusion criteria, such as having antibodies against the viral vector used in the therapy or having other significant medical conditions[1].

Study Objectives

The main goals of this clinical trial are[1]:

  1. To determine if AAV9-hSGSH is safe and well-tolerated by patients
  2. To assess how the body responds to the therapy, including the immune response
  3. To look for early signs of effectiveness in treating Sanfilippo A Syndrome
  4. To determine the best dose for future studies

Assessment Methods

The study will use various methods to evaluate the therapy’s effects[1], including:

  • Physical and neurological examinations
  • Blood and urine tests
  • Brain imaging (MRI)
  • Tests of cognitive and adaptive function
  • Quality of life assessments
  • Sleep studies

Potential Benefits and Considerations

While AAV9-hSGSH shows promise, it’s important to remember that this is still an experimental treatment[1]. Potential benefits could include slowing or stopping the progression of Sanfilippo A Syndrome, but there may also be risks and side effects that are not yet known. The clinical trial aims to better understand both the benefits and risks of this therapy.

For families affected by Sanfilippo A Syndrome, this research represents hope for a potential treatment for this currently incurable condition. However, it’s crucial to discuss any participation in clinical trials with healthcare providers and to understand that results are not guaranteed[1].

Aspect Details
Study Type Phase I/II clinical trial
Condition Mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)
Intervention Adeno-associated viral vector serotype 9 containing human sulfamidase gene (AAV9-CAG-coh-SGSH)
Administration Intracerebroventricular (ICV) injection
Primary Objectives Safety, tolerability, and immune response assessment
Secondary Objectives Initial efficacy, pharmacodynamic profile, biomarker evaluation
Key Eligibility Children aged 2+ with confirmed MPSIIIA, specific adaptive behavior scores, not wheelchair-dependent
Primary Endpoints Physical exams, blood tests, immune response, MRI, hepatic ultrasonography
Secondary Endpoints Enzyme activity, heparan sulfate levels, neurobehavioral assessments, quality of life measures

FAQ

  • What is Sanfilippo A syndrome? Sanfilippo A syndrome, also called Mucopolysaccharidosis type IIIA (MPSIIIA), is a rare genetic disorder that affects the body's ability to break down certain complex sugars. It typically leads to progressive brain damage and loss of developmental skills in children.
  • How does the gene therapy in this trial work? The therapy uses a modified virus (AAV9) to deliver a healthy copy of the sulfamidase gene (SGSH) to the patient's cells. This approach aims to provide the body with the ability to produce the missing enzyme, potentially slowing or stopping the progression of the disease.
  • How is the treatment administered? The treatment is administered through an intracerebroventricular (ICV) injection, which means it's delivered directly into the fluid-filled spaces within the brain. This method allows the therapy to reach the central nervous system more effectively.
  • Who is eligible for this clinical trial? The trial is open to male and female children aged 2 years or older with confirmed MPSIIIA. Participants must have certain levels of adaptive behavior, not be wheelchair-dependent, and meet other specific criteria related to their condition and overall health.
  • What are the main goals of this clinical trial? The primary objectives are to assess the safety and tolerability of the gene therapy, including immune responses. Secondary goals include evaluating the therapy's initial effectiveness, identifying useful biomarkers for tracking disease progression, and gathering data to inform future studies.

Ongoing Clinical Trials on Adeno-Associated Viral Vector Serotype 9 Containing The Human Sulfamidase Gene

  • Study on the Safety and Initial Effects of AAV9-CAG-coh-SGSH in Children with Sanfilippo A Syndrome

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Adeno-Associated Viral Vector: A modified virus used to deliver genetic material into cells for therapeutic purposes. It's considered safe because it doesn't cause disease in humans.
  • Intracerebroventricular (ICV): A method of administering medication directly into the fluid-filled spaces (ventricles) of the brain.
  • Mucopolysaccharidosis type IIIA (MPSIIIA): Also known as Sanfilippo A syndrome, it's a genetic disorder characterized by the body's inability to break down certain complex sugars, leading to progressive brain damage.
  • Sulfamidase: An enzyme that's deficient in people with Sanfilippo A syndrome. It's responsible for breaking down certain complex sugars in the body.
  • Gene therapy: A technique that uses genes to treat or prevent disease. In this case, it involves introducing a healthy copy of the SGSH gene to compensate for the faulty one.
  • Pharmacodynamic profile: The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Biomarker: A measurable indicator of a biological state or condition, used to track disease progression or treatment effectiveness.
  • Viral shedding: The release of virus particles from an infected person, which in this context is being monitored as part of the safety assessment.
  • Neutralizing antibodies (NAb): Antibodies that defend against specific viruses or other pathogens by neutralizing their biological effects.
  • Cerebrospinal fluid (CSF): The clear, colorless fluid that surrounds the brain and spinal cord, protecting them and providing nutrients.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-initial-effects-of-aav9-cag-coh-sgsh-in-children-with-sanfilippo-a-syndrome/